Neuroendocrine Tumor SPORE Center

Top SPORE Publications

Top Ten NET SPORE Pubications 2018-2019

Bellizzi A. Immunohistochemistry in the Diagnosis and Classification of Neuroendocrine Neoplasms: What Can Brown Do for You?Human Pathology 2019; [Epub ahead of print]  PMID: 31857137

Ear PH, Li G, Wu M, Abusada E, Bellizzi AM, Howe JR. Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids. Journal of visualized experiments.  2019 (152); PMID: 31657801

Howe J (Editor). Management of GI and Pancreatic neuroendocrine tumors in Surgical Oncology Clinics of North America (In Press). 
Table of Contents

  • O’Dorisio TM, O’Dorisio MS,  University of Iowa Departments of Internal Medicine and Pediatrics – “NET Overview”
  • Dillon J , University of Iowa Department of Internal Medicine – “Work up of GEP-NETs”
  • Bellizzi A, University of Iowa Department of Pathology  “Pathologic considerations in GEP-NETs”
  • Menda Y, Pollard J, McNeely, P.  University of Iowa Department of Radiology – “The role of functional imaging in GEP-NETs”
  • Howe J, Scott A. University of Iowa Department of Surgery – “Management of Small Bowel Neuroendocrine Tumors”
  • Keutgen X, Vaghaiwalla T, University of Chicago Department of Surgery – “Management of Pancreatic Neuroendocrine Tumors”
  • Libutti S, Laird A,  Rutgers Cancer Center Department of Surgery – “Management of Other Gastric and Duodenal Neuroendocrine Tumors”
  • Hrabe J, University of Iowa Department of Surgery – “Management of Colorectal Neuroendocrine Tumors (including appendix)”
  • Limbach K, Pommier R, Oregon Health Science University Department of Surgery – “Management of Metastatic GEPNETs”
  • Chandrekasaran C, University of Iowa Department of Internal Medicine – “Medical Management of GEP-NETs”
  • Bushnell D, Bodeker K, University of Iowa Departments of Radiology and Radiation Oncology – “Peptide Radioreceptor Therapy (PRRT)”

Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio MS, Reidy-Lagunes DL, Soulen MC, Strosberg JR. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med. 2018; 59:66-74. PMID: 29025982. 

Lee D, Li M, Bednarz B, Schultz MK. Modeling Cell and Tumor- Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy. Radiat Res. 2018; 190: 236-247. PMID: 29944461

Madsen MT, Menda Y, O'Dorisio TM, O'Dorisio MS. Technical Note: Single time point dose estimate for exponential clearance. Med Phys. 2018; 45: 2318-2324. PubMed PMID: 29577338

Menda Y, Madsen MT, O'Dorisio TM, Sunderland JJ, Watkins GL, Dillon JS, Mott SL, Schultz MK, Zamba GKD, Bushnell DL, O'Dorisio MS. 90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy. J Nucl Med. 2018; 59:1692-1698. PMID: 29523629

Scott AT, Weitz M, Breheny PJ, Ear PH, Darbro BW, Brown BJ, Braun TA, Li G, Amjad US, Kaemmer C, Maharjan CK, Quelle DE, Bellizzi AM, Chandrasekharan C, Dillon JS, O’Dorisio TM, Howe JR. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors.   Clinical Cancer Research (in press).

Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E. Health- Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018; 36: 2578- 2584. PMID: 29878866

Umesalma S, Kaemmer CA, Kohlmeyer JL, Letney B, Schab AM, Reilly JA, Sheehy RM, Hagen J, Tiwari N, Zhan F, Leidinger MR, O'Dorisio TM, Dillon J, Merrill RA, Meyerholz DK, Perl AL, Brown BJ, Braun TA, Scott AT, Ginader T, Taghiyev AF, Zamba GK, Howe JR, Strack S, Bellizzi AM, Narla G, *Umesalma S, Kaemmer CA, Kohlmeyer JL, Letney B, Schab AM, Reilly JA, Sheehy RM, Hagen J, Tiwari N, Zhan F, Leidinger MR, O'Dorisio TM, Dillon J, Merrill RA, Meyerholz DK, Perl AL, Brown BJ, Braun TA, Scott AT, Ginader T, Taghiyev AF, Zamba GK, Howe JR, Strack S, Bellizzi AM, Narla G, Darbro BW, Quelle FW, Quelle DE. RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth. J Clin Invest. 2019; 130:1641-1653. PMID: 30721156

  • View all NET SPORE team publications in PubMed